A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC

The study is being conducted to to explore the reasonable dosage and evaluate the efficacy and safety of HLX43 (Anti-PD-L1 ADC) in Combination with Serplulimab (Anti-PD-1 Recombinant Humanized Monoclonal Antibody) as Neoadjuvant Therapy in Subjects with Non-Small Cell Lung Cancer (NSCLC)

Trial Details

NCT ID

NCT07269782

Phase

PHASE2

Sponsor

Shanghai Henlius Biotech

Status

RECRUITING

Cancer Type

Non-Small Cell (NSCLC) Lung Cancer

Interventions

HLX43 DOSE 1
HLX43 DOSE 2
Serplulimab

Locations (sample)

Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

1\. Have a full understanding of the study content, process, and possible adverse reactions before the study, and sign the informed consent form (I…
2\. Aged ≥ 18 years and ≤ 75 years at the time of signing the ICF, male or female;
3\. Histologically or cytologically confirmed NSCLC;
4\. Diagnosed with stage II-IIIB NSCLC (according to the Union for International Cancer Control and the American Joint Committee on Cancer (AJCC) T…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →